The Latest Analyst Ratings For NeuroPace

Analysts' ratings for NeuroPace NPCE over the last quarter vary from bullish to bearish, as provided by 6 analysts.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for NeuroPace, presenting an average target of $16.33, a high estimate of $22.00, and a low estimate of $12.00. Observing a 48.45% increase, the current average has risen from the previous average price target of $11.00.

Analyzing Analyst Ratings: A Detailed Breakdown

The standing of NeuroPace among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeuroPace. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NeuroPace compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for NeuroPace's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NeuroPace's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on NeuroPace analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind NeuroPace

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Understanding the Numbers: NeuroPace's Finances

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Positive Revenue Trend: Examining NeuroPace's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 40.84% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -34.42%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): NeuroPace's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -33.5%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): NeuroPace's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.99%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: With a high debt-to-equity ratio of 3.51, NeuroPace faces challenges in effectively managing its debt levels, indicating potential financial strain.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.